Disophrol® Syrup versus Rinomar® Syrup in the Treatment of Allergic Rhinitis in Children

Abstract

In this single-blind study, the efficacy and safety of Disophrol® Syrup was compared to Rinomar® Syrup in seventy-eight paediatric patients with seasonal allergic rhinitis. Patients took 5–10 ml of the randomly assigned medication three to four times daily for a 2-week period. Severity of nasal obstruction, nasal secretion and mucosal swelling was graded and patient response to each week of therapy evaluated. An overall favourable response to Disophrol® Syrup was observed in thirty-one out of thirty-five (89%) patients and in thirty out of thirty-five (86%) patients in the Rinomar® group. No statistically significant difference in patient response to therapy between treatment groups was noted and no mentionable adverse reactions were reported.